Of note, in both cases, a true personalisation is yet to be achieved; it is more accurate to refer to stratified cancer medicine, given that for individual patients with hormone receptor positive or HER2-positive breast cancer treated with endocrine treatment or HER2 blockade, respectively, therapeutic resistance can occur. This evidence concerns the gene ERBB2 and breast cancer.